ILCN.org (ILCN/WCLC) ILCN.org (ILCN/WCLC)
twitter youtube facebook linkedin iaslc Home
  • Home
  • Featured Topics
    • Diagnostic Oncology
      • Early Detection & Screening
      • Evolving Standards of Care
      • Global Initiatives
    • Meeting News
      • Names & News
      • Nursing & Allied Health
      • Patient Advocacy
    • Radiation Oncology
      • Regulatory News
      • Risk Assessment and Reduction
      • Society News
    • Supportive & Palliative Care
      • Surgical Oncology
      • Tobacco & Smoking Cessation
      • WCLC News
  • WCLC News
  • About Us
Menu
  • Home
  • Featured Topics
    • Diagnostic Oncology
      • Early Detection & Screening
      • Evolving Standards of Care
      • Global Initiatives
    • Meeting News
      • Names & News
      • Nursing & Allied Health
      • Patient Advocacy
    • Radiation Oncology
      • Regulatory News
      • Risk Assessment and Reduction
      • Society News
    • Supportive & Palliative Care
      • Surgical Oncology
      • Tobacco & Smoking Cessation
      • WCLC News
  • WCLC News
  • About Us
loading...
Home Evolving Standards of Care

Growing Body of Evidence Highlights Potential Applications for Liquid Biopsy in Clinical Practice

Erin Jungmeyer
on: October 25, 2022In: Evolving Standards of Care, Meeting News
Growing Body of Evidence Highlights Potential Applications for Liquid Biopsy in Clinical Practice

During a lecture at NACLC 22, Dr. Christian Rolfo illustrated how ctDNA could be used to monitor progression and inform treatment decisions. Read more


When Perfect is the Enemy of Good: Investigators Compare Rigorous Clinical Trial Data to Real-World Experience

Kamya Sankar, MD
+more
on: October 25, 2022In: Evolving Standards of Care
When Perfect is the Enemy of Good: Investigators Compare Rigorous Clinical Trial Data to Real-World Experience

Using a real-world cohort of US veterans, researchers examine the effectiveness of durvalumab consolidation in unresectable stage III NSCLC. Read more

NACLC 22 Educational Session Explores the Rationale for Immune Checkpoint Inhibition

Erin Jungmeyer
on: October 11, 2022In: Evolving Standards of Care, Meeting News
NACLC 22 Educational Session Explores the Rationale for Immune Checkpoint Inhibition

During IASLC’s North America Conference on Lung Cancer, MD Anderson’s Dr. Tina Cascone reviewed the evidence for neoadjuvant and adjuvant therapy in NSCLC. Read more

Structure-Based Classification System for EGFR Mutations May Help Clinicians Personalize Treatments for More Patients

Xiuning Le, MD, PhD
+more
on: June 21, 2022In: Evolving Standards of Care
Structure-Based Classification System for EGFR Mutations May Help Clinicians Personalize Treatments for More Patients

Grouping mutations based on their likelihood of response to specific drug types in future EGFR TKI trials may eventually help physicians tailor treatments for patients with atypical mutations. Read more

More Robust Tools Needed to Predict who will Respond to Immune Checkpoint Inhibitors

Andrew McKenzie, PhD
on: June 21, 2022In: Evolving Standards of Care
More Robust Tools Needed to Predict who will Respond to Immune Checkpoint Inhibitors

Investigators at Sarah Cannon look to next-generation sequencing for molecular signatures that may correlate with response. Read more

Real-World Data from Taiwan Shows Stage Shift Has Improved Lung Cancer Survival Rates

Pan-Chyr Yang, MD, PhD
+more
on: June 07, 2022In: Evolving Standards of Care, Industry News & Regulatory Approvals
Real-World Data from Taiwan Shows Stage Shift Has Improved Lung Cancer Survival Rates

Researchers say increased screening of at-risk populations, including those who have never smoked, may improve survival more than any other strategy. Read more

Using Comparative Effectiveness Data Based on Non-Randomized Study Designs to Support Regulatory, Reimbursement Decision-Making

Sreeram Ramagopalan, PhD
on: June 07, 2022In: Evolving Standards of Care
Using Comparative Effectiveness Data Based on Non-Randomized Study Designs to Support Regulatory, Reimbursement Decision-Making

Study provides evidence to support the potential role of real-world data in consideration of technologies where only single-arm trial data exists. Read more

In Measuring Outcomes, a Longer-Term View May be Needed

Mark Hennon, MD
+more
on: June 07, 2022In: Evolving Standards of Care
In Measuring Outcomes, a Longer-Term View May be Needed

When publicly reported patient outcomes emerge, the data available to patients should paint the most complete picture possible. Read more

Alternative Dosing Strategies for Immune Checkpoint Inhibitors

Michiel Zietse, MSc
+more
on: May 24, 2022In: Evolving Standards of Care
Alternative Dosing Strategies for Immune Checkpoint Inhibitors

Combining fixed- and weight-based dosing approaches may reduce costs without compromising efficacy. Read more

Panel Explores Emerging Treatments and Sequencing Strategies for Patients with Advanced NSCLCs Driven by Rare Oncogenes

Beth Fand Incollingo
on: May 24, 2022In: Evolving Standards of Care, Meeting News
Panel Explores Emerging Treatments and Sequencing Strategies for Patients with Advanced NSCLCs Driven by Rare Oncogenes

During the 2022 European Lung Cancer Congress, experts reviewed evidence on drugs targeting MET exon 14 skipping mutations and RET, HER2, and BRAF alterations. Read more

‹12345›»
IASLC Logo
ILCN Editorial Group    IASLC.org   

Advertise with Us   

© 2023 IASLC. All Rights Reserved. Powered By TriStar Event Media, LLC   Privacy Policy